SG11201912224PA - Novel method for synthesizing amanitins - Google Patents

Novel method for synthesizing amanitins

Info

Publication number
SG11201912224PA
SG11201912224PA SG11201912224PA SG11201912224PA SG11201912224PA SG 11201912224P A SG11201912224P A SG 11201912224PA SG 11201912224P A SG11201912224P A SG 11201912224PA SG 11201912224P A SG11201912224P A SG 11201912224PA SG 11201912224P A SG11201912224P A SG 11201912224PA
Authority
SG
Singapore
Prior art keywords
amanitins
synthesizing
novel method
novel
synthesizing amanitins
Prior art date
Application number
SG11201912224PA
Other languages
English (en)
Inventor
Christian Lutz
Werner Simon
Susanne Werner-Simon
CHRISTOPH MüLLER
Thorsten Hechler
Michael Kulke
Original Assignee
Heidelberg Pharma Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Res Gmbh filed Critical Heidelberg Pharma Res Gmbh
Publication of SG11201912224PA publication Critical patent/SG11201912224PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6831Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
SG11201912224PA 2017-08-07 2018-08-06 Novel method for synthesizing amanitins SG11201912224PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17185182 2017-08-07
PCT/EP2018/071268 WO2019030173A1 (en) 2017-08-07 2018-08-06 NOVEL METHOD FOR SYNTHESIZING AMANITINES

Publications (1)

Publication Number Publication Date
SG11201912224PA true SG11201912224PA (en) 2020-01-30

Family

ID=59579417

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912224PA SG11201912224PA (en) 2017-08-07 2018-08-06 Novel method for synthesizing amanitins

Country Status (14)

Country Link
US (2) US10961277B2 (es)
EP (1) EP3665173A1 (es)
JP (1) JP7165720B2 (es)
KR (1) KR102674750B1 (es)
CN (1) CN111051310B (es)
AU (1) AU2018314668B2 (es)
BR (1) BR112020001345A2 (es)
CA (1) CA3066867A1 (es)
CL (1) CL2020000304A1 (es)
CO (1) CO2020001259A2 (es)
MX (1) MX2020001472A (es)
SG (1) SG11201912224PA (es)
WO (1) WO2019030173A1 (es)
ZA (1) ZA201908158B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661938A1 (en) 2017-08-07 2020-06-10 Heidelberg Pharma Research GmbH Novel method for synthesizing amanitins
SG11202008284XA (en) * 2017-08-18 2020-09-29 Sichuan Baili Pharm Co Ltd Non-natural amatoxin-type antibody conjugate
EP3773740A1 (en) * 2018-04-13 2021-02-17 Heidelberg Pharma Research GmbH Targeted amatoxin conjugate for the treatment of solid tumors
MX2021006533A (es) * 2018-12-11 2021-07-21 Heidelberg Pharma Res Gmbh Sintesis del (s)-6-hidroxitriptofano y derivados del mismo.
US20230135930A1 (en) 2019-04-24 2023-05-04 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
WO2021122744A1 (en) * 2019-12-16 2021-06-24 Heidelberg Pharma Research Gmbh Synthesis of amanin and its derivatives
CN115715294A (zh) * 2020-06-09 2023-02-24 海德堡医药研究有限责任公司 用于合成含硫醚肽的方法
EP4308169A2 (en) 2021-03-19 2024-01-24 Heidelberg Pharma Research GmbH B-lymphocyte specific amatoxin antibody conjugates
CN115385916B (zh) * 2021-07-01 2023-08-15 江苏师范大学 一种手性吲哚啉并吡咯化合物及其合成方法
WO2024094688A1 (en) 2022-11-01 2024-05-10 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
ATE521366T1 (de) 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
LT3192529T (lt) 2009-04-08 2020-06-25 Faulstich, Heinz, Dr. Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
SG174328A1 (en) 2009-04-08 2011-10-28 Deutsches Krebsforsch Amatoxin-armed target-binding moieties for the treatment of cancer
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
EP2436398B1 (en) 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkers
EP2497499A1 (en) * 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
WO2014043403A1 (en) * 2012-09-12 2014-03-20 Agensys, Inc. Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
US20160220687A1 (en) 2015-02-02 2016-08-04 National Guard Health Affairs Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer
US10842882B2 (en) * 2015-03-09 2020-11-24 Heidelberg Pharma Gmbh Amatoxin-antibody conjugates
WO2017089607A1 (en) 2015-11-27 2017-06-01 Heidelberg Pharma Gmbh Derivatives of gamma-amanitin

Also Published As

Publication number Publication date
BR112020001345A2 (pt) 2020-08-11
RU2020105484A3 (es) 2021-09-13
KR20200037207A (ko) 2020-04-08
CN111051310B (zh) 2022-11-08
KR102674750B1 (ko) 2024-06-13
US20210130412A1 (en) 2021-05-06
CL2020000304A1 (es) 2020-08-07
AU2018314668A1 (en) 2020-01-16
US11702451B2 (en) 2023-07-18
RU2020105484A (ru) 2021-08-05
JP7165720B2 (ja) 2022-11-04
AU2018314668B2 (en) 2022-06-02
CO2020001259A2 (es) 2020-02-18
CA3066867A1 (en) 2019-02-14
US10961277B2 (en) 2021-03-30
CN111051310A (zh) 2020-04-21
MX2020001472A (es) 2020-10-19
EP3665173A1 (en) 2020-06-17
WO2019030173A1 (en) 2019-02-14
JP2020529452A (ja) 2020-10-08
US20200181200A1 (en) 2020-06-11
ZA201908158B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
ZA201908158B (en) Novel method for synthesizing amanitins
GB201701109D0 (en) Method
GB201700937D0 (en) Synthesis method
IL274439A (en) Process for making Tapinaroff
EP3398957A4 (en) PROCESS FOR SYNTHESIS OF ETELCALCETIDE
EP3666729C0 (en) PROCESS FOR THE PRODUCTION OF NANO-SULFUR
IL266044B (en) Method for the production of 3-alkylsulfanyl-2-chloro-n-(1-alkyl-h1-tetrazol-5-yl)-4-trifluoromethyl-benzamides
GB201801768D0 (en) Synthesis method
GB201706778D0 (en) Method
GB201701396D0 (en) Novel alternating-phase synthesis method
IL283331A (en) Method for the preparation of n-phenylpyrazole-1-carboxamides
EP3423402A4 (en) PROCESS FOR SYNTHESIS OF NANODIAMANTS
GB201700352D0 (en) Method
PL3733651T3 (pl) Sposób wytwarzania kalkobutrolu
HK1256031A1 (zh) 新的4-苯並偶氮寧衍生物的製造方法
GB201702250D0 (en) Method
ZA201908452B (en) Improved process for preparing imetelstat
SG11201907182QA (en) Method for producing perfluoroalkadiene compounds
PL3511315T3 (pl) Sposób wytwarzania n-metylo-para-anizydyny
ZA201903463B (en) Method for preparing hexadecahydropyrene
SG11202004021RA (en) Production method for dihydroxyindoles
IL258898A (en) Method for synthesizing 2-alkyl-4-trifluoromethyl-3-alkylsulfonylbenzoic acids
GB201702096D0 (en) Method
GB201701941D0 (en) Method
GB201601558D0 (en) Method for producing 3-hydroxypropionamide